The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

IN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): C$14,921.92

Insider Selling (Last 12 Months): C$0.00

InMed Pharmaceuticals Insider Trading History Chart

InMed Pharmaceuticals Share Price & Price History

C^$0.00

+0.30 (1.20%)

As of 05/8/2021 12:59 AM ET

Days: 30 | 90 | 365

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

InMed Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2024	Eric Ashley Adams	Director	Buy	41,600	C$0.36	C$14,921.92
4/13/2022	Eric Ashley Adams	Director	Buy	8,560	C$1.07	C$9,167.76	44,843
1/24/2022	Bruce Colwill	Senior Officer	Buy	5,000	C$1.36	C$6,798.13	11,515
9/28/2021	Eric Ashley Adams	Director	Buy	11,400	C$2.31	C$26,379.14	27,483

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (TSE:IN)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: N/A

50 Day Range

MA: C$4.19

C$4.19

52 Week Range

Now: N/A

Volume

17,035 shs

Average Volume

29,552 shs

Market Capitalization

C$33.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?: InMed Pharmaceuticals' top insider shareholders include:
Eric Ashley Adams (Director)
Learn More about top insider investors at InMed Pharmaceuticals.

Move Your Money Before May 22

From Stansberry Research | Ad